Medication Assisted Treatment (MAT)
Medication assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies for the treatment of substance use disorders. A combination of medication and behavioral therapies is effective in the treatment of substance use disorders, and can help some people to sustain recovery.
- Implementation Resources
- Financing Resources
- Resources for Consumers and Families
- Resources for Physicians
- Other Resources
The Medication Assisted Treatment Implementation Checklist, from CIHS, outlines the key questions to consider before engaging in efforts to increase access to medication assisted treatment for addictions.
Expanding the Use of Medications to Treat Individuals with Substance Use Disorders outlines the lessons learned from safety-net providers as they explored the barriers and opportunities to implement use of medications for addictions treatment.
Procedures for Medication-Assisted Treatment of Alcohol or Opioid Dependence in Primary Care, a guidebook from RAND, provides an introduction to identifying and treating patients with substance use disorders in primary care settings
The Getting Started with Medication Assisted Treatment with Lessons from Advancing Recovery toolkit shares lessons from several Robert Wood Johnson Foundation Advancing Recovery project grantees to establish MAT programs in their organizations.
SAMHSA’s Opioid Overdose Prevention Toolkit provides communities and local governments with material to develop policies and practices to help prevent opioid-related overdoses and deaths.
SAMHSA’s Treatment Improvement Protocol (TIP) 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction provides information that physicians can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction.
SAMHSA’s TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs discusses MAT use in addiction treatment programs for opioid dependence.
SAMHSA’s TIP 49: Incorporating Alcohol Pharmacotherapies into Medical Practice provides guidance on implementing alcohol medications into routine medical practice.
American Society of Addiction Medicine’s Medicaid Benefits for the Treatment of Opioid Use Disorder Nationwide displays state Medicaid fee-for-service benefit coverage for medications approved to treat opioid dependence.
The Centers for Medicare & Medicaid Services’ Informational Bulletin highlights the use of FDA-approved medications in combination with evidence-based behavioral therapies to help persons with mental health and substance use disorders recover in a safe and cost-effective manner.
Financial Factors and the Implementation of Medications for Treating Opioid Use Disorders examines the relationships between organizational factors and the program-level implementation of MAT, with and emphasis on specific sources of funding, organizational structure and workforce resources.
Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment, a report from the American Society of Addiction Medicine, reviews the empirical economic evaluations of medications for the treatment of opioid dependence.
Developed by the Centers for Medicare & Medicaid Services Health Home Information Resource Center, the Designing Medicaid Health Homes for Individuals with Opioid Dependency: Considerations for States brief, highlights key features of approved health home models from Maryland, Rhode Island and Vermont that are tailored to individuals with opioid dependency.
The Training Tool for Residential Substance Abuse Treatment: Medication Assisted Treatment for Offender Populations curriculum outlines evidence-based practices for using MAT with criminal justice-involved individuals.
High Risk Opioid Use, a free online course from the National Institute on Drug Abuse (NIDA) and the Institute for Research, Education, and Training in Addictions (IRETA), shares informative graphics, videos and practice scenarios on opioids and the behavior pattern known as “doctor shopping.” Continuing Education Units are available for social workers, counselors, medical professionals, and others.
The ATTC's Medication-Assisted Treatment with Special Populations online training, developed for both non-physician treatment providers and physicians, is designed to enhance professionals' knowledge and skills to reach and educate special populations about MAT.
Prescribers’ Clinical Support System for Opioid Therapies (PCSS-O) is a national training and mentoring project that provides a variety of no cost CME programs on the safe and effective prescribing of opioid medications in the treatment of pain and/or opioid addiction.
SAMHSA's Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT) educates providers on the most effective medication-assisted treatments to serve patients in a variety of settings.
Learn about more upcoming training opportunities on our Substance Use Trainings page.
The Legal Action Center compiled Helpful Resources to Address Discrimination against People in Medication Assisted Treatment to educate employers, courts and others about MAT.
In My Own Words is a compilation of essays, developed in partnership with Faces & Voices of Recovery and the National Alliance for Medication Assisted Recovery, from individuals in long-term recovery supported by MAT.
SAMHSA's Medication-Assisted Treatment for Opioid Addiction: Friends and Families provides friends and families with information on MAT, their proper use and side effects, withdrawal symptoms and how medications fit within the recovery process.
The American Society of Addiction Medicine (ASAM) represents physicians who provide care for patients with addictions. Among ASAM’s resources are the Standards of Care for the Addiction Specialist Physician and Performance Measures: Applicable to the Addiction Specialist Physician.
The American Association of Addiction Psychiatry is an international organization that educates, influences, and encourages excellence in practice, policy and prevention for the field of addiction psychiatry.
SAMHSA's Medication-Assisted Treatment of Opioid Use Disorder Pocket Guide provides guidelines on various types of approved medications, screening and assessment tools and best practices for patient care for physicians using MAT for patients with opioid use disorder.
SAMHSA’s Advisory on Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update provides information on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
SAMHSA's General Principles for the Use of Pharmacological Agents To Treat Individuals With Co-Occurring Mental and Substance Use Disorders provides information to assist in the planning, delivery, and evaluation of pharmacologic approaches to support the recovery of individuals with co-occurring mental and substance use disorders.
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings from Starting Treatment with Agonist Replacement Therapies (START), a study from the Journal of Studies on Alcohol and Drugs, compares treatment outcomes with the type of treatment medication used.
SAMHSA's Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorders: A Brief Guide offers guidance on the use of extended-release injectable naltrexone for the treatment of an opioid use disorder. The guide covers patient assessment, initiating MAT, monitoring progress and deciding when to end treatment.
SAMHSA’s Division of Pharmacotherapies (DPT) supports the certification and accreditation of opioid treatment programs and oversees other regulatory activities necessary to implement SAMHSA regulation 42 CFR Part 8 on the use of FDA-approved opioid agonist medications (methadone, LAAM, and buprenorphine). DPT also supports the Drug Addiction Treatment Act of 2000 (DATA 2000), which allows qualified physicians to prescribe medications for the treatment of opioid addiction outside of traditional opioid treatment program settings.